Further studies are needed to better characterize the relationship between ROS1-GOPC fusion with the pathogenesis of nasopharyngeal papillary adenocarcinoma and response to TKIs such as crizotinib and lorlatinib toward this carcinoma. Here, GOPC is linked to carcinoma.